Capex of ~₹600 crore for FY27
Capital expenditure expected around ₹600 crore, including ₹200 crore for a new distribution center in the US and investments in API facility and IT.
GRANULESINDIA / guidance tracker
Keep management guidance in view.
Granules India · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
capex
Peptide CDMO to be PAT-positive in FY27
Management targets annual PAT-positive performance for the peptide CDMO business in FY27, despite quarterly variations.
Working capital to sales ratio maintained at ~33%
The company expects to keep net working capital at around 33% of sales in FY27, despite cost escalations.
Gagilapur site ready for FDA reinspection
Remediation activities are complete; the company is ready for FDA reinspection at any time, with nine product applications awaiting clearance.